Fuji Pharma (4554) · InitiativeRestated
Acquisition of exclusive negotiating rights for the menopausal disorder treatment PH80
First written in FY2024-Q1. 1 of 2 entries say "Restated". Latest entry: FY2024-Q2.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Acquisition of exclusive negotiation rights for the development and commercialization of PH80 in JapanA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024-Q2RestatedAnnual report
「The increase in R&D expenses resulting from recording as R&D expenses the consideration for exclusive negotiation rights covering the development and sale in Japan of a next-generation menopausal disorder treatment being developed by U.S.-based Vistagen in Phase 2」
The company continues to disclose the exclusive negotiation rights covering the development and sale in Japan of a Phase 2 menopausal disorder treatment being developed by U.S.-based Vistagen, as well as the recording of the consideration for those rights as R&D expenses. - FY2024-Q1First statedAnnual report
「Acquisition of Exclusive Negotiation Rights for PH80, a Menopausal Disorder Treatment」
The company disclosed for the first time that acquiring exclusive negotiation rights for PH80, a treatment for menopausal disorders, was a factor behind the increase in R&D expenses.